Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Other Working Capital Changes came in at $60638.0 in Q1 2026, up 110.27% on a QoQ basis from -$590645.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Other Working Capital Changes data on file, last reported at $60638.0 in Q1 2026.
- On a quarterly basis, Other Working Capital Changes changed N/A year-over-year to $60638.0 in Q1 2026; TTM through Mar 2026 was -$472094.0, a 510.58% decrease from a year earlier, with the FY2025 full-year figure at -$532732.0, down 510.74% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $60638.0, up from -$590645.0 in the prior quarter.
- Over the last five years, Other Working Capital Changes for IKT reached as high as $759312.0 in Q1 2023 and fell as low as -$590645.0 in Q4 2025.
- Historically, Other Working Capital Changes has averaged -$13841.6 across 5 years, with a median of -$6912.5 in 2022.
- On a YoY basis, Other Working Capital Changes climbed as much as 324.88% in 2023 and fell as far as 17238400.0% in 2023.
- Year by year, Other Working Capital Changes stood at -$13824.0 in 2022, then plunged by 601.81% to -$97018.0 in 2023, then soared by 233.69% to $129702.0 in 2024, then sank by 555.39% to -$590645.0 in 2025, then soared by 110.27% to $60638.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were $60638.0 in Q1 2026, -$590645.0 in Q4 2025, and -$14660.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,638.00 |
| Mar 31, 2026 | 60,638.00 |
| Mar 31, 2026 | 60,638.00 |
| Dec 31, 2025 | -590,645.00 |
| Dec 31, 2025 | -590,645.00 |
| Dec 31, 2025 | -590,645.00 |
| Sep 30, 2025 | -14,660.00 |
| Sep 30, 2025 | -14,660.00 |
| Sep 30, 2025 | -14,660.00 |
| Jun 30, 2025 | 72,573.00 |
| Jun 30, 2025 | 72,573.00 |
| Jun 30, 2025 | 72,573.00 |
| Dec 31, 2024 | 129,702.00 |
| Dec 31, 2024 | 129,702.00 |
| Dec 31, 2024 | 129,702.00 |
| Sep 30, 2024 | -62,389.00 |
| Sep 30, 2024 | -62,389.00 |
| Sep 30, 2024 | -62,389.00 |
| Jun 30, 2024 | 47,670.00 |
| Jun 30, 2024 | 47,670.00 |